Skip to main content
Top
Published in: Supportive Care in Cancer 11/2017

01-11-2017 | Original Article

Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer

Authors: Hui-Chun Hsu, Su-Yu Tsai, Shang-Liang Wu, Shiow-Roug Jeang, Mei-Yao Ho, Wen-Shiung Liou, An-Jen Chiang, Tsung-Hsien Chang

Published in: Supportive Care in Cancer | Issue 11/2017

Login to get access

Abstract

Purpose

This study aimed to assess the incidence and difference of side effects among six courses of chemotherapy (C/T) in gynecological cancer patients.

Methods

The study period was from Sep. 2010 to Dec. 2011 at the Kaohsiung Veterans General Hospital in Taiwan. The treating protocols, courses, and drugs of C/T in patient were considered according to the different malignant cancers and clinical conditions. The patient data of age, marriage status, education, religion, and experiences of C/T were collected. The patients’ or their families’ reported side effects of C/T were recorded daily from the beginning of C/T to the 10th day after C/T in each cycle and every course of C/T.

Results

Total 89 patients enrolled into the study received total 450 courses of C/T. The mean age was 54.52 ± 11.02. Ovarian cancer was the most common malignant disease (64.0%). The most often combination of drugs used was Taxol and carboplatin (40.9%). Patients complained peripheral numbness of limbs, with the highest incidence of 58.6%. The side effects with incidence about 50% were decreased fatigue (55.0%) and hair loss (49.9%). Other side effects with different levels of incidence were also noticed, such as lack of appetite, changes in taste, and muscle ache. The incidences of peripheral limb numbness and hair loss were increased with following courses of C/T. The high incidence of fatigue did not show variation between different courses of C/T.

Conclusion

This study revealed the incidence of side effects and occurrence timing during C/T in patients with gynecological cancer. These data provide substantial information to patients and their families to understand the potential side effects of C/T courses, which might increase their compliance in receiving adjuvant C/T. Relieving the side effects in C/T would be important to improve their quality of daily life and treatment willingness.
Literature
1.
go back to reference American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, Atlanta American Cancer Society (2015) Cancer facts and figures 2015. American Cancer Society, Atlanta
7.
go back to reference Gloeckler Ries LA et al (2013) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8(6):541–552CrossRef Gloeckler Ries LA et al (2013) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8(6):541–552CrossRef
8.
go back to reference Sun CC, Ramirez PT, Bodurka DC (2007) Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18–29CrossRef Sun CC, Ramirez PT, Bodurka DC (2007) Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 4(1):18–29CrossRef
9.
go back to reference Seretny M et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. PAIN® 155(12):2461–2470CrossRef Seretny M et al (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. PAIN® 155(12):2461–2470CrossRef
10.
go back to reference Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C et al (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14:151–161 Mock V, Atkinson A, Barsevick A, Cella D, Cimprich B, Cleeland C et al (2000) NCCN practice guidelines for cancer-related fatigue. Oncology (Williston Park) 14:151–161
11.
go back to reference Cella D, Davis K, Breitbart W, Curt G (2001) Fatigue coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRef Cella D, Davis K, Breitbart W, Curt G (2001) Fatigue coalition. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19:3385–3391CrossRef
12.
go back to reference Ruffer JU, Flechtner H, Tralls P, Josting A, Sieber M, Lathan B et al (2003) Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186CrossRef Ruffer JU, Flechtner H, Tralls P, Josting A, Sieber M, Lathan B et al (2003) Fatigue in long-term survivors of Hodgkin’s lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer 39:2179–2186CrossRef
13.
go back to reference Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ et al (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3 Suppl 2):4–12PubMed
14.
go back to reference Lou Y, Yates P, McCarthy A, Wang H (2013) Fatigue self-management: a survey of Chinese cancer patients undergoing chemotherapy. J Clin Nurs 22(7–8):1053–1065CrossRef Lou Y, Yates P, McCarthy A, Wang H (2013) Fatigue self-management: a survey of Chinese cancer patients undergoing chemotherapy. J Clin Nurs 22(7–8):1053–1065CrossRef
15.
go back to reference Shields K, Craig C, Baxter L, Renda L, Pipe J, Monk B, Chase D (2015) Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy. Gynecol Oncol 137(3):596CrossRef Shields K, Craig C, Baxter L, Renda L, Pipe J, Monk B, Chase D (2015) Cancer-related fatigue in gynecologic oncology patients undergoing chemotherapy. Gynecol Oncol 137(3):596CrossRef
16.
go back to reference Wang SC, Borison HL (1950) The vomiting center: a critical experimental analysis. Arch Neurol Psychiatr 63:928–941CrossRef Wang SC, Borison HL (1950) The vomiting center: a critical experimental analysis. Arch Neurol Psychiatr 63:928–941CrossRef
17.
go back to reference Miller AD, Wilson VJ (1983) “Vomiting center” reanalyzed: an electrical stimulation study. Brain res 270:154–158CrossRef Miller AD, Wilson VJ (1983) “Vomiting center” reanalyzed: an electrical stimulation study. Brain res 270:154–158CrossRef
18.
go back to reference Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000–1006CrossRef Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000–1006CrossRef
19.
go back to reference Pater JL, Lofters WS, Zee B et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181–185CrossRef Pater JL, Lofters WS, Zee B et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181–185CrossRef
20.
go back to reference Paul J, Hesketh N (2008) Chemotherapy-induced nausea and vomiting. Engl J Med 358:2482–2494CrossRef Paul J, Hesketh N (2008) Chemotherapy-induced nausea and vomiting. Engl J Med 358:2482–2494CrossRef
21.
go back to reference Kris MG et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947CrossRef Kris MG et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947CrossRef
22.
go back to reference Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994CrossRef Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971–2994CrossRef
23.
go back to reference Jordan K, Schmoll HJ, Aapro MS (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61:162–175CrossRef Jordan K, Schmoll HJ, Aapro MS (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61:162–175CrossRef
Metadata
Title
Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer
Authors
Hui-Chun Hsu
Su-Yu Tsai
Shang-Liang Wu
Shiow-Roug Jeang
Mei-Yao Ho
Wen-Shiung Liou
An-Jen Chiang
Tsung-Hsien Chang
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3768-7

Other articles of this Issue 11/2017

Supportive Care in Cancer 11/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine